Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 29%
Buy 14%
Hold 14%
Sell 29%
Strong Sell 14%

Bulls say

Novavax Inc has shown improved financial positioning with a revised revenue guidance for FY25, reflecting an increase from $1-$1.05 billion to $1.04-$1.06 billion. The company has recorded $225 million in milestones from Sanofi (SNY), with an expected additional $50 million in the fourth quarter, boosting its financial outlook and cash flow for operations. Furthermore, the working capital has strengthened to $544.7 million, demonstrating the company's ability to manage its resources effectively and focus on its core competencies within the vaccine development space.

Bears say

Novavax Inc's financial outlook is burdened by significant cash burn, with cash equivalents decreasing to $778.2 million from $938.2 million due to operational expenses, despite some offset from milestone payments and debt refinancing. The company has experienced a 17% year-over-year revenue decline, primarily attributed to the transition of lead commercial responsibility to Sanofi for the upcoming COVID season, which has also led to a drastic 55% year-over-year decrease in third-quarter revenue. Additionally, concerns persist regarding the competitiveness of Novavax's pipeline products, such as NanoFlu, as their differentiation from existing vaccines is uncertain, posing further risks to future revenue generation and overall valuation.

Novavax (NVAX) has been analyzed by 7 analysts, with a consensus rating of Hold. 29% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 29% advise Selling, and 14% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 7 analysts, Novavax (NVAX) has a Hold consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.